Johnson & Johnson has agreed to buy Ollin Biosciences, a clinical-stage biopharmaceutical company developing therapies for serious eye diseases.
Johnson & Johnson has agreed to buy Ollin Biosciences, a clinical-stage biopharmaceutical company developing therapies for serious eye diseases.